N/A N=78 Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease
Congenital Heart Disease
Primary: Feasibility of Enrollment — 40; 38 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Project 4, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Pregnant Women
Tobacco Use Disorder
Primary: Total Cigarettes Per Day — 16.31; 18.36 Cigarettes per day
N/A N=30 HypErthermia as an Additional Treatment for the Biology and Experience of Depression: Study 2
Major Depressive Disorder · Depression
Primary: Net Promoter Score, and Enrollment Likelihood — 7.73; 8.00; 4.13; 4.29 score on a scale
N/A N=7 Sleep Well 24 (SWELL24) Healthy Sleep-Wake Behaviors in Older Adults
Insomnia Disorder
Primary: Sleep Efficiency — 95.1 percent
Phase 2 N=76 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma · Liver Cancer
Primary: Tumor Response — 0; 7; 47; 11 Participants
Early Phase 1 N=64 Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder
Alcohol Use Disorder
Primary: Startle Eyeblink Electromyographic (EMG) Response to Stress With an Acute Dose of Suvorexant — 0.01; .24; 0.01; -0.18 Standardized residual scores — p=.19
Phase 3 N=24 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease
Primary: Number of Patients Achieving a Response (R) at Week 24 — 8; 2 Participants
Phase 3 N=2,747 An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival Per BICR — 5.06; 4.17; 5.55; 4.90 months
N/A N=151 Study of Forceps Cannulation During ERCP
Post-ERCP Acute Pancreatitis
Primary: Cannulation Success Rate and Difficult Cannulation Rate — 70; 68; 0; 13 Participants
N/A N=1,184 Message-Based Psychotherapy and Digital Treatment Sequences for Depression
Study Adherence · Depressive Disorder
Primary: Change in Neuro-QOL - Ability to Participate in Social Roles and Activities — 39.55; 39.57; 41.65; 42.07 T-score
N/A N=90 Clinical Utility of a Non Endoscopic Device EsoCheck and Biomarker EsoGuard as Alternative to Endoscopy for Screening for Barrett's Esophagus in At Risk Population
Barrett Esophagus
Primary: The Impact of EsoCheck/EsoGuard on Provider's Decision for Upper Endoscopy Referral — 382; 211 Cases
Phase 2 N=686 Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel
Acne Vulgaris
Primary: Absolute Change From Baseline to Week 12 in Lesion Counts. — -29.9; -19.7; -27.9 lesion counts
Phase 2 N=62 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Acute Myeloid Leukemia With FLT3/ITD Mutation · Acute Myeloid Leukemia With Gene Mutations · Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM
Primary: Disease-free Survival (DFS) — .5 proportion of participants
N/A N=301 A Nurse-led Intervention to Extend the Veteran HIV Treatment Cascade for Cardiovascular Disease Prevention
Cardiovascular Disease · Hypertension · Care Coordination
Primary: Mean Systolic Blood Pressure — 134.6; 133.3 mmHg
N/A N=87 Neurofeedback Impact on Veterans With mTBI
Concussion · mTBI · Post-Concussive Symptoms
Primary: Headache Impact Test (HIT-6) — 53.2; 61.4; 49.2; 60.9 score on a scale — p=<.0001